8-K: GeoVax Labs Faces Nasdaq Delisting Over Low Stock Price

GeoVax Labs Inc. has received a delisting determination from Nasdaq due to its common stock trading below the $1.00 minimum bid price for 30 consecutive business days.

Summary

• GeoVax Labs Inc. received a notification from Nasdaq on August 27, 2026, indicating that its common stock is subject to delisting.
• The determination is based on the closing bid price of the company's common stock falling below $1.00 per share for 30 consecutive business days, from July 16, 2026, to August 26, 2026.
• This violates Nasdaq Listing Rule 5550(a)(2).
• Due to a 1-for-25 reverse stock split executed on January 12, 2026, the company is not eligible for the standard 180-day compliance period.
• The company also previously received a notification regarding non-compliance with the minimum $2,500,000 stockholders equity requirement (Nasdaq Listing Rule 5550(b)).
• Trading suspension is expected to commence on September 8, 2026, if no hearing is requested.
• GeoVax Labs plans to request a hearing before the Nasdaq Hearings Panel by the September 3, 2026 deadline.
• A timely hearing request will halt further actions pending a decision.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development due to the delisting notice from Nasdaq, indicating potential financial distress and reduced investor confidence.

Positives

• The company plans to request a hearing before the Nasdaq Hearings Panel, which will stay further actions pending a decision.
• The common stock will remain listed and continue trading on Nasdaq during the appeal process.

Negatives

• GeoVax Labs Inc. has received a determination from Nasdaq to delist its common stock.
• The company's stock has traded below the $1.00 minimum bid price for 30 consecutive business days.
• The company is not eligible for the standard 180-day compliance period due to a recent reverse stock split.
• The company previously failed to meet the minimum stockholders equity requirement of $2,500,000.
• Trading suspension is anticipated to begin on September 8, 2026, if no hearing is requested.

Risks

• The primary risk is the delisting of the company's common stock from Nasdaq, which could significantly reduce liquidity and investor interest.
• There is no assurance that the Nasdaq Hearings Panel will grant the company's request for continued listing.
• The company may not ultimately regain compliance with all applicable Nasdaq listing requirements.
• The company's shares may not remain listed on Nasdaq following the hearing.
• Failure to regain compliance could lead to trading on over-the-counter markets, which typically have lower liquidity and higher volatility.

Future Outlook

The company's future listing status on Nasdaq is uncertain and depends on the outcome of a hearing before the Nasdaq Hearings Panel. There is no guarantee of regaining compliance or remaining listed.

Management Comments

• The Company plans to timely request a hearing before the Nasdaq Hearings Panel.
• A timely hearing request will stay any further actions.
• There can be no assurance that the Hearings Panel will grant the Companys request for continued listing or that the Company will ultimately regain compliance with all applicable Nasdaq listing requirements or that the Companys shares of common stock will remain listed on Nasdaq following the hearing.

Industry Context

StockSavvy.ai notes that Nasdaq delisting notices due to low stock price are a common occurrence for companies facing significant financial or operational challenges. This situation often signals underlying issues with business performance, investor sentiment, or market perception.

Stakeholder Impact

• Shareholders: Potential for significant loss of investment value, reduced liquidity, and difficulty trading shares if delisted.
• Creditors: Increased risk of default if the company's financial situation deteriorates further due to delisting.
• Employees: Potential for reduced morale and job security if the company faces severe financial distress.

Next Steps

• Request a hearing before the Nasdaq Hearings Panel by September 3, 2026.
• Present the case for continued listing to the Nasdaq Hearings Panel.
• Await a final determination from the Hearings Panel regarding the company's listing status.

Key Dates

Recommendation

The delisting notice from Nasdaq, coupled with previous non-compliance with equity requirements and the ineligibility for a standard compliance period due to a reverse split, presents a severe risk to the company's viability and investor confidence. The uncertainty surrounding the appeal process and the lack of positive catalysts in this filing warrant a sell recommendation.

Keywords

delisting, Nasdaq, stock price, compliance, listing requirements, reverse stock split, equity requirement, hearing request